Publications

December 8, 2025

American Society of Hematology Annual Meeting

Correlation between Treatment-Emergent Cytopenias and Clinical Response with Imetelstat (IME) in Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (LR-MDS): Analysis from the IMerge Trial

Long-Term Outcomes from Randomized, Double-Blind, Placebo-Controlled, Phase 3 IMerge Trial of Imetelstat for Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Correlation between Interleukin (IL)-8 and Tumor Necrosis Factor (TNF)-Alpha Levels and Overall Survival in Patients (Pts) with Myelofibrosis (MF) Relapsed or Refractory (R/R) to a Janus-Associated Kinase Inhibitor (JAKi) Treated with Imetelstat (IME) in the IMbark Trial

IMproveMF: Phase 1b Trial of Imetelstat Plus Ruxolitinib in Patients with Intermediate-2 or High-Risk Myelofibrosis

A Phase II Study Evaluating the Efficacy and Safety of Imetelstat in Patients with Advanced Myelodysplastic Neoplasms or AML Failing HMA-based Therapy: Interim Analysis Results of the IMpress Study